Jury not out: There is ongoing trial to answer your question but previous studies suggest ABVD superior. That said, factors such as radiotx and personal immune response to Hodgkin D need to be considered. Fail cases to conventional chemoradiotx appear to respond to immune therapy, ie. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma N Engl J Med 2015; 372:311-319. Confirm ur dx 1st step
Answered 7/12/2015
2.6k views
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question